Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2018-08
ICR Author
Marsden,
Yap, Christina
Author
Pratt, G
Yap, C
Oldreive, C
Slade, D
Bishop, R
Griffiths, M
Dyer, MJS
Fegan, C
Oscier, D
Pettitt, A
Matutes, E
Devereux, S
Allsup, D
Bloor, A
Hillmen, P
Follows, G
Rule, S
Moss, P
Stankovic, T
Show allShow less
Type
Journal Article
Metadata
Show full item record
URI
https://repository.icr.ac.uk/handle/internal/1518
DOI
https://doi.org/10.1111/bjh.14793
Collections
  • Clinical Studies
Subject
Humans
Lymphoma, Mantle-Cell
Lymphoproliferative Disorders
DNA Damage
Recurrence
Piperazines
Phthalazines
Survival Analysis
Maximum Tolerated Dose
Aged
Middle Aged
Female
Male
Tumor Suppressor Protein p53
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Prolymphocytic, T-Cell
Ataxia Telangiectasia Mutated Proteins
Poly(ADP-ribose) Polymerase Inhibitors
Research team
Clinical Trials & Statistics Unit
Language
eng
License start date
2018-08
Citation
British journal of haematology, 2018, 182 (3), pp. 429 - 433

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.